Find policies, billing codes, payers, states, and providers
HCPCS Level II J0911: Taurolidine-Heparin Catheter Lock for Hemodialysis
HCPCS Level II code J0911 represents the instillation of taurolidine 1.35 mg combined with heparin sodium 100 units used as a central venous catheter lock for adult patients receiving chronic hemodialysis. This code identifies a specialized vascular access maintenance procedure that supports catheter patency and infection prevention, making it relevant to dialysis providers, outpatient infusion centers, and payers managing chronic renal replacement therapy populations nationwide. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service setting, benchmarking considerations for reimbursement and utilization, common billing modifiers and coding practice notes, and relevant payer policy highlights where available. The publication also outlines documentation elements and potential audit focal points for claims involving catheter lock solutions. Data not available in the input is noted where applicable; this summary focuses on nationally applicable implications rather than state-specific rules.
Customize your policy alerts
Sign up for hcpcs J0911 policy alerts
Get alerted when payer policies referencing J0911 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J0911 describes the instillation of taurolidine 1.35 mg and heparin sodium 100 units as a central venous catheter lock intended for adult patients receiving chronic hemodialysis. The service type is a catheter lock instillation used to maintain catheter patency and reduce infection risk in long-term hemodialysis access. The typical site of service is an outpatient dialysis center or other ambulatory setting where chronic hemodialysis is administered.